# Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)

> **NCT07357103** · PHASE4 · NOT_YET_RECRUITING · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 416 (estimated)

## Conditions studied

- Pneumocystis
- Pneumocystis Infection
- Pneumocystis Carinii Infection
- Pneumocystis Carinii; Infection, Resulting From HIV Disease
- Pneumocystis Jirovecii Pneumonia
- Pneumocystis Jirovecii Infection
- Pneumocystosis Associated With AIDS
- Pneumocystosis; Pneumonia (Etiology)

## Interventions

- **DRUG:** Clindamycin + primaquine
- **DRUG:** Pentamidine
- **DRUG:** Atovaquone

## Key facts

- **NCT ID:** NCT07357103
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2029-03
- **Final completion:** 2029-09
- **Target enrollment:** 416 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07357103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07357103, "Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07357103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*